MIRO(Delisted)
Miromatrix Medical·NASDAQ
--
--(--)
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About MIRO
Miromatrix Medical Inc.
A life sciences company that pioneers a novel technology for bioengineering fully transplantable organs
6455 Flying Cloud Drive, Suite 107, Eden Prairie, MN 55344
--
Miromatrix Medical Inc., was incorporated in Delaware in 2009. They are a life sciences company pioneering new technologies for bioengineering fully transplantable human organs to help save and improve patient lives. Organ disease is a major public health problem. According to the Transplant Foundation of America, there are an estimated 114,000 people in the United States waiting for life-saving organ transplants, and an average of 20 people die every day due to lack of available organs. They have developed a proprietary perfusion technology platform for bioengineered organs that they believe will be effectively expanded to address the shortage of available human organs. Their initial development focus was on the human liver and kidney, and they have demonstrated in preclinical studies the ability to bioengineer these organs with functional vasculature and vital organ functions.
Company Financials
EPS
MIRO has released its 2023 Q3 earnings. EPS was reported at -0.24, versus the expected -0.21, missing expectations. The chart below visualizes how MIRO has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
MIRO has released its 2023 Q3 earnings report, with revenue of 11.18K, reflecting a YoY change of -9.83%, and net profit of -6.45M, showing a YoY change of 15.40%. The Sankey diagram below clearly presents MIRO's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
Related Symbols
You can ask Aime
No Data
